Cantor Fitzgerald Forecasts Weaker Earnings for Alector

Alector, Inc. (NASDAQ:ALEC) – Investment analysts at Cantor Fitzgerald lowered their FY2025 earnings estimates for shares of Alector in a research report issued on Wednesday, October 1st. Cantor Fitzgerald analyst P. Stavropoulos now anticipates that the company will post earnings per share of ($1.53) for the year, down from their previous estimate of ($1.45). The consensus estimate for Alector’s current full-year earnings is ($1.88) per share. Cantor Fitzgerald also issued estimates for Alector’s FY2026 earnings at ($1.43) EPS.

Alector (NASDAQ:ALEC) last announced its quarterly earnings results on Thursday, August 7th. The company reported ($0.30) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.15. The firm had revenue of $7.87 million for the quarter, compared to the consensus estimate of $2.76 million. Alector had a negative return on equity of 112.06% and a negative net margin of 142.10%. Alector has set its FY 2025 guidance at EPS.

Several other research analysts have also recently weighed in on ALEC. BTIG Research reissued a “buy” rating and issued a $5.00 price target on shares of Alector in a report on Thursday, September 25th. Mizuho upgraded shares of Alector from a “neutral” rating to an “outperform” rating and increased their price objective for the stock from $2.50 to $3.50 in a research note on Monday, July 28th. Weiss Ratings restated a “sell (d-)” rating on shares of Alector in a research note on Saturday, September 27th. Finally, Wall Street Zen lowered Alector from a “hold” rating to a “sell” rating in a research note on Friday, September 26th. Four research analysts have rated the stock with a Buy rating, one has issued a Hold rating and three have issued a Sell rating to the stock. Based on data from MarketBeat, Alector currently has a consensus rating of “Hold” and an average price target of $4.17.

Alector Trading Up 5.1%

ALEC stock opened at $3.32 on Friday. Alector has a one year low of $0.87 and a one year high of $6.14. The stock has a market cap of $336.02 million, a price-to-earnings ratio of -2.86 and a beta of 0.99. The company has a fifty day moving average price of $2.47 and a two-hundred day moving average price of $1.72. The company has a debt-to-equity ratio of 0.13, a current ratio of 3.78 and a quick ratio of 3.78.

Institutional Trading of Alector

Hedge funds and other institutional investors have recently made changes to their positions in the company. Millennium Management LLC increased its stake in shares of Alector by 45.8% in the fourth quarter. Millennium Management LLC now owns 74,685 shares of the company’s stock valued at $141,000 after buying an additional 23,467 shares during the period. Two Sigma Investments LP boosted its position in Alector by 55.4% during the 4th quarter. Two Sigma Investments LP now owns 407,989 shares of the company’s stock worth $771,000 after buying an additional 145,467 shares during the period. Squarepoint Ops LLC bought a new stake in Alector during the 4th quarter worth approximately $25,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in Alector by 12.2% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 160,570 shares of the company’s stock valued at $303,000 after acquiring an additional 17,509 shares during the period. Finally, Bank of New York Mellon Corp increased its position in Alector by 8.1% in the 1st quarter. Bank of New York Mellon Corp now owns 249,494 shares of the company’s stock valued at $307,000 after acquiring an additional 18,765 shares during the period. 85.83% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Alector

In related news, Director Paula Hammond sold 14,000 shares of the business’s stock in a transaction on Tuesday, August 26th. The stock was sold at an average price of $2.36, for a total transaction of $33,040.00. Following the sale, the director owned 74,909 shares in the company, valued at $176,785.24. The trade was a 15.75% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 9.70% of the stock is currently owned by company insiders.

Alector Company Profile

Alector, Inc, a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases.